2,989 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by Disciplined Investors L.L.C.

Disciplined Investors L.L.C. acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 2,989 shares of the biopharmaceutical company's stock, valued at approximately $269,000.

A number of other hedge funds have also recently modified their holdings of the stock. State Street Corp increased its holdings in Gilead Sciences by 1.4% during the 3rd quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company's stock valued at $5,044,795,000 after acquiring an additional 841,776 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Gilead Sciences by 3.1% during the 4th quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock valued at $3,293,822,000 after buying an additional 1,058,331 shares during the period. Geode Capital Management LLC boosted its stake in shares of Gilead Sciences by 2.7% in the fourth quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company's stock valued at $2,608,337,000 after purchasing an additional 749,047 shares during the period. Norges Bank bought a new position in Gilead Sciences during the 4th quarter valued at $1,789,254,000. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Gilead Sciences by 3.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 8,002,779 shares of the biopharmaceutical company's stock valued at $739,217,000 after buying an additional 249,804 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on GILD. Piper Sandler raised their price target on Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a report on Wednesday, February 12th. JPMorgan Chase & Co. raised their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Wells Fargo & Company upped their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. The Goldman Sachs Group upped their price target on Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a report on Wednesday, February 12th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $105.12.

Gilead Sciences Stock Up 1.1 %

Shares of GILD stock traded up $1.11 during mid-day trading on Tuesday, hitting $106.63. The company's stock had a trading volume of 3,281,780 shares, compared to its average volume of 7,363,104. The stock has a market cap of $132.78 billion, a price-to-earnings ratio of 288.71, a PEG ratio of 0.71 and a beta of 0.32. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The business has a 50-day moving average price of $107.50 and a 200 day moving average price of $96.13.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were given a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.96%. The ex-dividend date was Friday, March 14th. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's dividend payout ratio (DPR) is 854.05%.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $97.22, for a total value of $13,822,739.60. Following the completion of the sale, the chief financial officer now owns 129,873 shares in the company, valued at approximately $12,626,253.06. This represents a 52.26 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders sold 302,785 shares of company stock worth $30,503,250. 0.16% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.